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Abstract
Background: The results of previous studies elsewhere have indicated that GB virus C (GBV-C) infection is frequent in
patients infected with the human immunodeficiency virus type 1 (HIV-1) due to similar transmission routes of both viruses.
The aim of this study was to determine the prevalence, incidence density and genotypic characteristics of GBV-C in this
population.
Methodology/Principal Findings: The study population included 233 patients from a cohort primarily comprised of
homosexual men recently infected with HIV-1 in Sa˜o Paulo, Brazil. The presence of GBV-C RNA was determined in plasma
samples by reverse transcriptase-nested polymerase chain reaction and quantified by real-time PCR. GBV-C genotypes were
determined by direct sequencing. HIV viral load, CD4+ T lymphocyte and CD8+ T lymphocyte count were also tested in all
patients. The overall prevalence of GBV-C infection was 0.23 (95% CI: 0.18 to 0.29) in the study group. There was no
significant difference between patients with and without GBV-C infection and Glycoprotein E2 antibody presence regarding
age, sex, HIV-1 viral load, CD4+ and CD8+T cell counts and treatment with antiretroviral drugs. An inverse correlation was
observed between GBV-C and HIV-1 loads at enrollment and after one year. Also, a positive but not significant correlation
was observed between GBV-C load and CD4+ T lymphocyte. Phylogenetic analysis of the GBV-C isolates revealed the
presence of genotype 1 and genotype 2, these sub classified into subtype 2a and 2b.
Conclusion/Significance: GBV-C infection is common in recently HIV -1 infected patients in Sao Paulo, Brazil and the
predominant genotype is 2b. This study provides the first report of the GBV-C prevalence at the time of diagnosis of HIV-1
and the incidence density of GBV-C infection in one year.
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Introduction
The GB virus type C (GBV-C, also known as hepatitis G virus)
is an enveloped, positive-sense, single- stranded RNA virus
belonging to the family Flaviviridae, and is closely related to the
hepatitis C virus (HCV). It has been proposed to be classified as
members of a fourth genus in the Flaviviridae family, named
Pegivirus [1]. GBV-C appears to be lymphotropic and has been
shown to replicate in vitro in peripheral blood mononuclear cells
CD4+ and CD8+ T lymphocytes and B lymphocytes [2,3]. It was
first identified in 1995 in serum from individuals with idiopathic
hepatitis [4,5,6,7]. Although infection with GBV-C is common in
the HIV-1 infected population, it has not been associated with
chronic disease or affect the clinical course of hepatitis A, B, or C
infection(s) [8]. Over the past several years a number of studies
have found GBV-C to exert a favorable impact on the course of
HIV-1 [9,10,11,12,13] or HCV infections [14,15] with a lower
mortality rate, slower progression to AIDS, and longer survival
once AIDS has developed. Others studies have failed to
demonstrate a similar effect [16,17,18,19]. Likewise, the discrep-
ancy between results of some studies could be explained by
different stage of HIV-1 infection among the different population
studied [20].
GBV-C is prevalent among subjects highly exposed to HIV-1
acquisition and those with asymptomatic or symptomatic HIV
infection [21], as it is probably sexually transmitted. It is also
known as having transmitted via blood, blood products,
intravenous drug use, and from mother to child through
pregnancy and/or delivery [22,23].
The geographical distribution is related to the co-evolution of
the viruses with humans during the migrations along the history,
suggesting that GBV-C is an ancient virus [24,25]. The
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phylogenetics analyses of GBV-C isolates have demonstrated the
presence of multiple genotypes with consistent geographical
clustering. Moreover, there is a high degree of nucleotide and
amino acid sequence conservation between isolates from widely
separated geographic areas [26]. Genotype 1 is found in West
Africa [27]; genotype 2 (sub-classified as either 2a or 2b) in the
United States and Europe [26]; genotype 3 in Asia [28,29,30];
genotype 4 in Myanmar and Vietnam [31]; genotype 5 in South
Africa [32]; and genotype 6 in [33,34]. A geographic sub-cluster
within the GBV-C genotype 2 has been recently identified in
Portugal [35].
The frequency of GBV-C infection in patients with HIV-1
ranges from as low as 13.5% [36] in a Argentinean population of
HCV+/HIV+ hemophilic patients, from 24% to 37% in a group
comprised predominantly by male homosexuals in the United
States [37], in a similar Danish cohort [37,38,39] in a Brazilian
group of heterosexual HIV-1 infected participants [37,38,39] and
45% in France, in a cohort of HIV-1 infected patients where
intravenous drug use and homosexuality were identified as major
transmission risk factors [40]. The frequency of GBV-C exposure
in children with chronic renal failure has been shown to be high as
51% comparing to the healthy group with 8%, and may be the
result of frequent blood transfusions [41]. Moreover, the GBV-C
genotypes were not analyzed. Ramezani et al. studying 82 Iranian
HIV positive patients found a GBV-C prevalence of 10.97% and
there was no statistically significant difference in the prevalence
between the two groups studied: 13.5% in IDUs (13.5%) vs.
heterosexuals (6.7%)[42]. The results of this study indicate that the
parental route of transmission may be an important method of
viral transmission, though other routes ie sexual [43] and
household contact [44] may also play a role in GBV-C
epidemiology. The prevalence of GBV-C infection was 9% in a
group of 64 hemodialysis patients from Caracas, Venezuela [45],
13.6%, all genotype 2, in a total of 104 hemodialysis patients living
in Tehran [46]. In an Amerindian population from Venezuela a
high prevalence of GBV-C genotype 3 was observed, ranging from
5% (9 out of 162) in the West to 25% (14 out of 56) in the South
region of the country [45]. The prevalence of GBV-C was 9.7%
among 545 blood donors in Sao Paulo, Brazil [47], 8.3% in 1,039
healthy individuals, also from Sa˜o Paulo, Brazil [48] or 1% from
478 Iranian volunteer blood donors [49].
Following its discovery and description; several studies began
reporting GBV-C virus prevalence in HIV-1 uninfected patients
from different groups and regions in Brazil. First reports were
initially available from hemodialysis patients with prevalence of
15%, or from patients with chronic liver diseases with a prevalence
of 19% and 7% respectively [50,51,52]. The spread of GBV-C
infection is also described in the general population ranging from
2% to 18% and the predominant genotypes were 2a, 2b and 1
[47,53,54,55,56,57,58].
Since the available data on the GBV-C epidemiology among
Brazilian HIV-1-infected patients is limited to cross-sectional
studies, the aim of this work was to determine the prevalence,
incidence density, and genotypic distribution of GBV-C in a
cohort of recently HIV-1-infected subjects in Sao Paulo, Brazil.
Methods
Ethics Statement
Informed written consent was obtained from all the patients and
the study was approved by the Ethics Committees and the
Institutional Review Board of the Federal University of Sao Paulo
[#0919/01].
Study sample
Subjects included in this study were individuals seeking HIV
testing at counseling and testing centers located in Sao Paulo,
Brazil. Recent HIV-1-infection was determined by the Serologic
Testing Algorithm for Recent HIV Seroconversion (STARHS),
and individuals were included in the study when they had a
negative desensitized ELISA HIV-test, that could indicate an
incomplete antibody response as a consequence of recent HIV-1
infection [59,60].
The volunteers were evaluated for clinical and virological status,
as well as, for the presence of other co-infections at enrollment
[61] and after one year of follow up. Plasma and peripheral blood
mononuclear cells (PBMC) were obtained, the latter from
leukapheresis with Ficoll-Paque (Pharmacia Biotech, Uppsala,
Sweden) density gradient centrifugation. The age, gender, race,
HIV transmission route, and laboratory data are described in
Table 1.
The initiation of antiretroviral therapy followed the Ministry of
Health Guidelines for HIV therapy in Brazil [62] which
recommends treatment for patients with CD4+ T cell counts
bellow 200 cells/mL, as well as, to consider treatment for patients
with CD4+ T cell counts between 200 and 350 cells/mL, or in the
presence of clinical AIDS. As the standard clinical practice in this
cohort, treatment was initiated when CD4+ T cell counts were
confirmed bellow 300 cells/mL.
CD4+ T cell counts and Viral Load (VL) quantification
The CD4+ and CD8+ T cell counts were measured by using
lymphocyte staining with CD3, CD4, and CD8 conjugated
monoclonal antibodies (TriTest, BD Biosciences, San Diego,
California, USA). HIV plasma viral load was determined using the
Amplicor HIV-1 Monitor test, version 1.5 (Roche Diagnostics
Systems, Branchburg, New Jersey, USA) with a detection limit of
400 copies/ml until January 2007. This test was subsequently
replaced by the branched DNA assay (VersantH HIV-1 RNA 3.0
ASSAY (bDNA), Siemens Healthcare Diagnostics, Deerfield, IL,
USA) with a detection limit of 50 copies/ml.
At baseline (visit 1), upon the confirmation of recent HIV-1-
infection, all included volunteers, to be referred to as Group 1, had
a plasma sample tested for the presence of GBV-C RNA, and were
classified as having active GBV-C infection (GBV-C RNA present)
or no GBV-C infection (GBV-C RNA absent). All volunteers from
Group 1 with active GBV-C infection, also had their GBV-C viral
load, and GBV-C genotype determined at visit 1.
From the total of 233 volunteers belonging to Group 1, a
subgroup of 131 subjects, referred as Group 2, was also tested at
visit 1 for the presence of E2 antibodies against GBV-C envelope
glycoprotein E2 (anti-E2), and was classified as having active
GBV-C infection (GBV-C RNA present, and anti-E2 absent), past
GBV-C infection (GBV-C RNA absent, and anti-E2 present), and
susceptible to GBV-C infection (GBV-C RNA absent, and anti-E2
absent). These volunteers were also tested for the presence of
GBV-C RNA and E2 antibody after one year of the enrollment
(visit 5), after the confirmation of recent HIV-1-infection. They
were reclassified at visit 5 as cases of cleared GBV-C infection
(GBV-C RNA absent), or new cases of active GBV-C infection
(GBV-C RNA present), respectively.
Detection of E2 antibody
As markers of GBV-C RNA clearance and prior exposure [63]
plasma E2 antibodies were detected using an immunoassay using
recombinant E2 (mPlate Anti-Hgenv test; Roche Diagnostics,
kindly provided by Dietmar Zdunek), in accordance with the
manufacturer’s instructions. Plates were incubated with diluted
GBV-C in Recent HIV Infection
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(1:20) serum, and E2 antibodies were detected using anti-human
immunoglobulin G peroxidase conjugate and 2,29-azinobis (3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) substrate. In accor-
dance with the manufacturer’s cutoff, an optical density (OD) of
less than 0.10 was considered to be negative, and an OD of at least
0.10 was considered to be positive.
Detection and quantification of GB virus type C RNA
Viral RNA was extracted from 140 mL plasma samples using
QIAamp Viral RNA Mini Kit (QIAGEN Inc, CA), according to
the manufacturer’s instructions. The quantity of 5 mL of the RNA
extracted was diluted in a mix containing 150 ng of random
primer (Random Primer, Pharmacia Biotech, Sweden) and
0.5 mM deoxyribonucleosides triphosphate (dNTPs by Invitrogen
Inc., Carlsbad, California, USA); the solution was kept at 65uC for
5 minutes. Complementary DNA (cDNA) synthesis was carried
out by the addition of 200 U of Super Script III Reverse
transcriptase (Invitrogen Inc, CA) in a buffer solution with 10 U of
ribonuclease inhibitor (Invitrogen Inc, CA) at 25uC for 5 minutes,
50uC for 60 minutes and 70uC for 15 minutes at a final volume of
20 mL.
A fragment of 344 bp from the 59 non-coding region (59 NCR)
was amplified by nested RT PCR using the followings primers
located at positions 108 (59-AGGTGGTGGATGGGTGAT-39;
sense, outer), 134 (59-TGGTAGGTCGTAAATCCCGGT-39;
sense, inner), 476 (59-GGAGCTGGGTGGCCCCATGCAT-39;
antisense, inner) and 531 (59-TGCCACCCGCCCTCACCC-
GAA-39; antisense, outer) [32,64]. Amplification consisted of 40
cycles for both first and second rounds of PCR, with the following
incubation times and temperatures: 94uC 30 s, 50uC 30 s, and
72uC 30 s for the first round and 94uC 30 s, 60uC 30 s, and 72uC
30 s for the second round. After amplification, 5 ml of the PCR
product was used for electrophoresis analysis on a 2% agarose gel.
The GBV-C load was quantified in all GBV-C RNA-positive
samples in triplicate by Real-Time PCR using a TaqMan PCR
detection kit (Perkin-Elmer Applied Biosystems, Foster City,
California, USA). The following oligonucleotides were used in
the real-time PCR located at positions 111–130 (59-
GTGGTGGATGGGTGATGACA-39; sense), 192-171(59-
GACCCACCTATAGTGGCTACCA-39, antisense). The GBV-
C specific probe tagged with fluorescence FAM CCGGGATT-
TACGACCTACC NFQ (MGB, Minor Groove Binder; NFQ,
nonfluorescent quencher) antisense 154–136 numbered according
to Accession NC_001710.1 [65] was synthesized by Applied
Biosystems. A strongly positive GBV-C RNA plasma bag from an
HIV negative blood donor was obtained and serial dilutions of it
were used to estimate the assay endpoint sensitivity. This
corresponded to a 10000X dilution of the original plasma. On
the basis of that, this standard plasma bag was estimated to contain
10 000 detectable units of GBV-C RNA and was therefore used on
real-time assays to quantify viral load in HIV patients. Results are
provided in comparison to this ‘‘standard’’. The limit of detection
was one arbitrary unit (au)/mL.
Sequencing and genotyping
The 344 bp PCR product was purified with the QIAquick kit
(QIAGEN, Hilden, Germany), and directly sequenced using Big
Dye Terminator Cycle Sequencing Ready Reaction (Applied
Biosystems, Foster City, USA) according to the manufacturers
protocol. The sequences were edited using the SEQUENCHER
program (Gene Codes Corporation Ann Arbor, Michigan, USA)
and aligned with the reference sequences of the five main
Table 1. Characteristics and comparisson of the population from Group 1, according to their GBV-C status at baseline, N = 233.
GBV-C RNA Positive n = 54 GBV-C RNA Negative n = 179 p
Gender (n,%)
Male 50 (92.6) 162 (90.5) 0.63*
Ethnicity (n,%)
White 29 (53.7) 103 (60.23) 0.69*
Mulato 11 (20.37) 34 (19.88)
Black 4 (7.41) 13 (7.6)
Other 10 (18.52) 21 (12.28)
Exposure (n,%)
MSM 45 (83.33) 146 (82.95) 0.97*
Hetero 9 (16.67) 30 (17.05)
Age, in years
median (IQR 25-75) 27.61 (24–35) 31.48 (26–38) 0.018**
CD4+ Tcells, in cells/mm3
median (IQR 25–75) 512.5 (401–604) 521 (398–709) 0.99**
CD8+ Tcells, in cells/mm3
median (IQR 25–75) 940 (641–1,151) 877 (601–1,243) 0.76**
HIV RNA (log copies/mL)
median (IQR 25–75) 4.30 (3.60–4.91) 4.29 (3.59–4.81) 0.87**
GBV-C RNA (log au/mL)
median (IQR 25–75) 3.06 (2.44–4.44)
*Pearson’s chi-squared test.
**Wilcoxon rank-sum test adjusted for ties.
doi:10.1371/journal.pone.0018407.t001
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genotypes obtained from GenBank. The phylogenetic analysis was
carried out in the 59 noncoding region (59 NCR) fragments with
the PHYLIP 3.5c program. Bootstrap values were determined on
1000 replicates of the sequence data with the SEQBOOT
program. Phylogenetic relationships were constructed using the
Neighbor-Joining method, and the pairwise distances were
calculated by the maximum likelihood with the DNADIST
program. The consensus tree was found with the CONSENSE
program. The GBV-C sequences used in this study were deposited
in GenBank under accession numbers GQ227302-49.
Statistical Analysis
The demographic and laboratorial characteristics of volunteers
at baseline (visit 1) were compared within Group 1, among the
different GBV-C genotypes from the active GBV-C infection cases
of Group 1, and within Group 2. The categorical variables were
compared by the Pearson’s chi-squared test, or by the two-sided
Fisher’s exact test, while the continuous variables were compared
by the Wilcoxon rank-sum test, or the Kruskal-Wallis test, both
adjusted for ties when necessary. The p values for the Kruskal-
Wallis statistic were obtained by the chi-square approximation.
Group 1 was used to calculate the prevalence of active GBV-C
infection at visit 1, and Group 2 was used to calculate the
prevalence of past GBV-C infection at visit 1, along with their
exact binomial 95% confidence intervals. We also calculate the
incidence density referred as the total number of cases divided by
the total number of person-years of follow-up. The cases of cleared
GBV-C infection from Group 1 were used to calculate the
incidence density of cleared GBV-C infection at visit 5, and the
new cases of active GBV-C infection from Group 2 were used to
calculate the incidence density of active GBV-C infection at visit 5,
along with their exact Poisson 95% confidence intervals. Linear
regression was used to evaluate the impact of GBV-C genotype on
GBV-C viral load at visit 1, and included the volunteers with
active GBV-C infection from Group 1. The initial full model was
adjusted for age (continuous) and gender. The GBV-C viral load
between visit 1 and visit 5 was compared, among those volunteers
with confirmed GBV-C active infection at both visits, by the
Wilcoxon signed rank test.
Two linear regression models were built to evaluate if active
GBV-C infection had any impact on CD4+ T cell count, or on
HIV viral load at visit 1, and two logistic regression models were
built to evaluate if laboratory and demographic characteristics
could predict active or past GBV-C infection at visit 1. The
volunteers from Group 1 were included in the models evaluating
active infection, while the ones from Group 2 were included in the
model evaluating past infection. These analyses included in the
initial full model age (continuous), gender, ethnicity, and sexual
exposure. In addition, the initial linear regression models included
CD4+ T cell count at visit 1, when evaluating the impact on HIV
viral load, or HIV viral load at visit 1, when evaluating the impact
on CD4+ T cell count, while the logistic regression models
included both.
The variables included in the final linear regression models were
selected by the change-in-estimate procedure with backward
elimination [66]. At each stage, the variable for which removal
caused the smallest change in the regression coefficient of the
exposure of interest was removed, given that this change was
smaller than 10%. The backward stepwise regression procedure,
with a p value of 0.05 for backward-selection, was used to obtain
the final models for the logistic regression analysis. All statistical
tests used a significance level of 0.05 and were performed using
STATA 10.0 (Stata Corporation, Texas).
Results
Study Population
A total of 233 antiretroviral naı¨ve subjects were enrolled in the
cohort at the moment of the study. One of the major
characteristics of the targeted patient population is the majority
of men who have sex with men (MSM); other demographic
characteristics of the cohort are included In the Table 1. Cross-
sectional analyses at time of enrollment (visit 1) and one year after
seroconversion (visit 5) were performed. All samples were tested
for the presence of GBV-C RNA and a sub-population of 131
patients was tested for the presence of E2 antibody.
Prevalence and Incidence Density of GB Virus C infection
At enrollment, 54 cases of active GBV-C infection (defined by
the presence of GBV-C RNA without E2 antibody) and 31 cases of
past GBV-C infection (defined by the presence of E2 antibody
without GBV-C RNA) were identified, resulting in a prevalence of
0.23 [95% confidence interval (95% CI), 0.18 to 0.29], and of 0.24
(95% CI: 0.16 to 0.32) respectively. Among the volunteers
susceptible to GBV-C infection at visit 1, two new cases of active
GBV-C infection were identified after one year (visit 5), resulting
in an incidence density (ID) of 3.6 per 100 person-years (95% CI:
0.44 to 13.1). Among the volunteers with active GBV-C infection
at visit 1, four cleared the GBV-C viremia at visit 5, resulting in an
ID of 10 per 100 person-years (95% CI: 3 to 28). Interestingly, no
patient developed E2 antibodies after clearance of GBV-C RNA
and also no case of viremia reactivation in antibody positive
individuals was observed. Moreover, there was no association
between clearance of GBV-C viremia and its genotypes. From
those who cleared the virus, only one had begun antiretroviral
therapy and among the incident cases, two out of three had
initiated antiretroviral therapy after 48 and 204 days of
enrollment.
There were no statistically significant differences in the
demographic or laboratory characteristics at visit 1 within Group
1 (Table 1) or Group 2 (Table 2) and active GBV-C infection did
not have any significant impact on CD4+ T cell count or on HIV-
1 viral load.
CD4+ T cell counts and VL quantification
Overall, in the group of GBV-C RNA positive, the median
CD4+ T lymphocyte count was 513 cells/mL (interquartile range
25–75% [IQR], 401–604), the median CD8+ T lymphocyte count
was 940 cells/mL (IQR 641–1,151), and the median HIV-1 viral
load was 19,800 copies/mL (IQR 3,960–80,500) or 4.3 log10
copies/mL (IQR 3.60–4.91). In the group of GBV-C RNA
negative participants, the median CD4+ T lymphocyte count was
521 cells/mL (IQR 398–709), the median CD8+ T lymphocyte
count was 877 cells/mL (IQR 601–1,243), and the median HIV-1
viral load of 19,607 copies/mL (IQR 3,916–63,935), or 4.3 log10
copies/mL (IQR 3.60–4.81) (Table 1).
The median viral load of GBV-C at baseline was 1,157 au/mL
(IQR 274–27,800), corresponding to 3.06 log10 au/mL (IQR
2.44–4.44) (Table 1), and at visit 5 was 11,851 au/mL (IQR 406–
62,236), or 4.07 log10 au/mL (IQR 2.06–4.79) (p value = 0.17).
Amino Acid Sequence Analyses and Genotype
Distribution
At visit 1, 45 GBV-C isolates, out of 54 GBV-C RNA-positive
samples, could be amplified and the phylogenetic tree revealed
that 5 (11%) GBV-C strains were grouped as genotype 1, 13
(28.8%) as genotype 2a, and 27 (60%) as genotype 2b (Figure 1).
Among the volunteers from Group 1 with active GBV-C infection,
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the GBV-C viral load at visit 1 was significantly different
(p = 0.007) among genotypes 1, 2a, and 2b (Table 3). The final
linear regression model evaluating the impact of GBV-C genotype
on GBV-C viral load was adjusted only for age. The mean GBV-C
viral load, in the log10 scale, of genotype 1 was 2.4 units higher
than of genotype 2b (p = 0.001), of genotype 2a was 1 unit higher
than of genotype 2b (p = 0.019), and there was no significant
difference between genotypes 1 and 2a (p = 0.6).
Relationship between GBV-C infection, HIV-1 viral laod,
CD4+ Tcell count and age
The final logistic regression model including volunteers from Group
1 had only age as a statistically significant predictor of active GBV-C
infection (p = 0.04). It demonstrated an inverse association of age and
active GBV-C infection, which can be translated into a predicted
probability of active GBV-C infection of 0.19 among volunteers with
36 years of age (percentile 75), and of 0.27 among volunteers with 25
years of age (percentile 25), a 0.08 change in probability. The final
logistic regression model including volunteers from Group 2 did not
find any significant association of laboratory or demographic
characteristics with past GBV-C infection (data not shown).
We then proceeded with correlation analyses between GBV-C
viral load and HIV-1 viral load or CD4+ T cell counts. At the
earlier visit, an inverse but not significant correlation (r =20.24,
p = 0.1071) was found, along with no apparent correlation
between the GBV-C load and the CD4+ cell count (r = 0.09,
p = 0.5069) (data not shown). After one year, when we performed
the same analysis excluding those on antiretroviral therapy, a
persistent trend of negative correlation between the GBV-C load
and the HIV-1 load was documented (r =20.30, p = 0.1608). At
the same time, a trend of positive correlation between the GBV-C
load and the CD4+ cell count (r = 0.43, p = 0.07) was observed in
the group of untreated patients (data not shown).
Discussion
In this study we determined the prevalence, incidence density,
and genotypic characteristics of GBV-C virus infection in a cohort
of 233 patients recently infected with HIV-1 from different
counseling and testing centers located in Sao Paulo, Brazil.
This cohort was comprised primarily of ethnically diverse young
men predominantly infected by HIV-1 clade B virus who reported
having sex with men, and no intravenous drug users [67].
Evidence of GBV-C infection was documented in 47% of
participants (23% with ongoing viral replication and 24% with
evidence of cleared infection). The prevalence of GBV-C found in
our cohort was similar to previous reports in other HIV-1-infected
groups from North America [10] and Europe [9,38], though
higher than reported in Argentina [36]. Additionally, our results
indicate a higher prevalence than previous studies performed in
non HIV-infected Brazilians [47,53,54,56,68,69,70]. The preva-
lence of GBV-C will likely vary by population but it appears clear
that GBV-C infection is more common in groups with risk factors
for percutaneous and sexual transmission of infectious agents. The
inverse relationship observed between age and active infection
may indicate prior infection in older patients who were exposed to
GBV-C at a time before HIV-1 infection and progressively cleared
this virus. On the other hand, the lack of association between past
infection and age may suggest that younger individuals are
possibly engaged in higher risk behavior(s) for GBV-C acquisition,
a hypothesis that warrants further investigation.
After one year, the incidence density of clearance of GBV-C
was found to be of 10 cases per 100 person-years, similar to 9%
observed in a larger study cohort [10], whereas among individuals
susceptible to GBV-C RNA infection, the incidence density of new
cases was three-fold lower. This incidence density value represents
only one subject (1.6%), a lower rate than observed in a group of
patients co-infected with GBV-C, hepatitis C, and HIV-1 viruses
Table 2. Characteristics of the population from Group 2, according to their E2 Antibody status at baseline, N = 131.
RNA (+) n = 31 E2 (+) n = 31 RNA/E2 (2) n = 69 p
Gender (n,%)
Male 28 (90.32) 26 (83.87) 63 (91.3) 0.52*
Ethnicity (n,%)
White 18 (58.06) 21 (67.74) 40 (58.82) 0.12*
Mulato 6 (19.35) 3 (9.68) 17 (25)
Black 4 (12.9) 7 (22.58) 5 (7.35)
Other 3 (9.68) 6 (8.82)
Exposure 0.9*
MSM 23 (74.19) 24 (77.42) 54 (78.26)
Hetero 8 (25.81) 7 (22.58) 15 (21.74)
Age, in years
median (IQR 25–75) 29.07 (24–35) 31.48 (25–36) 32.54 (26–39) 0.099**
CD4+ Tcells, in cells/mm3
median (IQR 25–75) 534 (389–607) 542 (381–837) 519 (417–727) 0.84**
CD8+ Tcells, in cells/mm3
median (IQR 25–75) 952 (633–1,121) 952 (637–1,459) 877 (579–1,143) 0.4**
HIV RNA (log copies/mL)
median (IQR 25–75) 4.30 (3.54–4.93) 4.39 (3.28–4.69) 4.11 (3.64–4.77) 0.88**
*Pearson’s chi-squared test.
**Kruskal-Wallis test (chi-square approximation) adjusted for tie´s.
doi:10.1371/journal.pone.0018407.t002
GBV-C in Recent HIV Infection
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18407
GBV-C in Recent HIV Infection
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18407
on antiretroviral therapy [71]. The factors that influence the
clearance of GBV-C are not known and may depend upon the
presence of sufficient numbers of CD4+ T cells [9,72]. Our result
do not support the hypothesis of antiretroviral therapy interfering
with GBV-C clearance, considering that only one out of the four
subjects who cleared GBV-C RNA was on treatment. Likewise,
the role of E2 antibody development in GBV-C RNA clearance
remains unclear. In our study, E2 antibody was not developed in
the patients who cleared de GBV-C virus, verified at visit 5 (after
one year of enrollment) therefore, our results may underestimate
the lifetime of the GBV-C infection. Similarly the lacking of E2
antibody detection may represent first, the absence of sensitivity of
the nucleic acid tests to detect low levels of viral replication by the
conventional methods. The viral replication can also occur at
higher or lower detection rates, as occurs with HCV in some cases.
Second, longer window period between the clearance of viremia
and the antibodies detection may exist. Third, the lack of
specificity of the EIA for E2 antibody can lead to undetectable
level of antibodies. Since our analysis was based on two time points
we do not know when GBV-C was cleared and whether more time
is required for antibody detection. Moreover, we still do not know
if the spontaneous resolution of GBV-C viremia is necessarily
followed by the appearance of E2 antibodies [72]. Therefore, it is
also important to know the GBV-C genotype if we consider that
difference in GBV-C strain circulating within populations might
affect the progression of HIV disease [73,74].
We also cannot rule out fluctuating GBV-C RNA levels in the
four subjects with undetectable results after baseline positive
viremia, which may bounce back up. A longer follow-up would
necessary to assess this possibility.
At enrollment, dual HIV-1 and GBV-C viremic subjects
exhibited a trend toward an inverse correlation between GBV-C
and HIV-1 viral load, which was maintained after one year of
follow-up if they remained off antiretroviral therapy. We
hypothesized that if GBV-C exerted a beneficial effect on the
immune system of the HIV infected patient, the GBV-C load
should correlate with higher CD4+ T cell counts or lower HIV
RNA copies/ml, reflecting inhibition of HIV replication. A
negative correlation between GBV-C load and HIV-1 load as
well as positive correlation between GBV-C load and CD4+ T cell
counts has been demonstrated previously among chronically HIV-
infected patients [10]. In our study, we found a trend towards a
negative correlation between the GBV-C load and the HIV-1 load
but no correlation between the GBV-C load and the number of
CD4+ cells at the earlier visit. The study population may explain
these findings as it is composed of recently HIV-1 infected
Table 3. Characteristics of the GBV-C positive population, according to their genotypic distribution, N = 45.
Genotype
1 n = 5 2a n = 13 2b n = 27 p
Gender (n,%)
Male 5 (100) 13 (100) 23 (85) 0.41*
Ethnicity (n,%)
White 2 (40) 8 (62) 15 (55) 0.94*
Mulato 2 (40) 2 (15) 4 (15)
Black 0 (0) 1 (8) 3 (11)
Other 1 (20) 2 (15) 5 (19)
Exposure 0.49*
MSM 4 (80) 12 (92) 20 (74)
Hetero 1 (20) 1 (8) 7 (26)
Age, in years
median (IQR 25–75) 23.23 (23–24) 25.76 (24–31) 29.08 (26–35) 0.15**
CD4+ Tcells, in cells/mm3
median (IQR 25–75) 372 (358–546) 590 (403–812) 573 (450–676) 0.38**
CD8+ Tcells, in cells/mm3
median (IQR 25–75) 752 (649–1,049) 1,002 (763–1,211) 933 (633–1,158) 0.47**
HIV RNA (log copies/mL)
median (IQR 25–75) 4.63 (3.6–4.95) 4.45 (3.75–5.10) 3.95 (3.24–4.92) 0.54**
GBV-C RNA (log au/mL)
median (IQR 25–75) 5.04 (4.47–5.35) 3.92 (3.00–4.86) 2.70 (2.05–3.07) 0.007**
*Two-sided Fisher’s exact test.
**Kruskal-Wallis test (chi-square approximation).
doi:10.1371/journal.pone.0018407.t003
Figure 1. Phylogenetic tree of GB virus C (GBV-C) isolates. Phylogenetic tree of Brazilian GB virus C (GBV-C) clinical isolates based on the
nucleotide sequences. Tree was constructed by the Neighbor-Joining (NJ) program, and the pair wise distances between sequences were calculated
by the DNADIST program. Values near branches indicate bootstrap support based on 1000 replicates. Relevant bootstrap values .60 (out of 100) are
shown.
doi:10.1371/journal.pone.0018407.g001
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individuals. Additionally, the median viral load of GBV-C at one
year after enrollment was higher comparing to the baseline levels,
but this change was not statistically significant. We cannot
conclude whether the increase in GBV-C viral load is due to
viral transactivation exerted by HIV-1 replication, or due to
immunodeficiency progression. Nevertheless our data is consistent
with a recent study showing that GBV-C viremia appears to
reactivate in HIV-infected individuals, resulting in a significant
increase of GBV-C viral load [21].
The results of the phylogenetic analysis identified genotypes 1,
2a, and 2b, consistent with other reports in Brazil [47,53,54] in
which the frequency of viral isolates is similar, such as the USA,
Africa, and Europe. The isolates were not clustered and the
presence of genotypes 1 and 2 in Sao Paulo was not unexpected,
given the high percentage of individual reporting African or
European origins in this city. The extent of the GBV-C sequence
diversity is limited. Consequently, little information is available for
the geographical distribution of the genotypes and the influence on
the clinical outcome. A previous report has shown that CD4+ T
cell counts tended to be lower in patients infected with genotype 2a
compared to those with genotype 2b [73]. In our study, the
genotype 1 presented higher values of GBV-C viral load, followed
by the genotype 2a and 2b, both at similar levels. It is difficult to
conclude whether the GBV-C genotype influences the clinical
outcome due to the limited number of cases in this cohort after
such stratification. Larger studies, including different regions of
Brazil, may demonstrate if the genotype has a stronger impact in
the clinical course of HIV-1 infection or on surrogate markers of
progression.
Despite the particular sampling of the cohort, predominantly
MSM, and the small sample size after stratification by GBV-C
genotype, we performed detailed evaluations of the prevalence and
genotyping distribution in a cohort of recently HIV-1 infected
subjects. This is the first report of density incidence in the GBV-C
infection in this population from Southeast Brazil. Potential
diverse distribution of GBV-C virus may also account for different
interaction between both viruses in different regions of the world,
which should be further investigated.
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